| Document Date: 2014-11-05 17:48:08
Open Document File Size: 205,91 KBShare Result on Facebook
City Cincinnati / / Company Administrator Intellectual Property Department Provider Synergies L.L.C. / Irritable Bowel Syndrome Review / Provider Synergies L.L.C. / Magellan Medicaid Administration Inc. / / Country United States / / Currency pence / / / Event FDA Phase / Product Issues / / IndustryTerm Treatment for irritable bowel syndrome / pharmaceutical / food / food intolerance / Treatment of irritable bowel syndrome / / MedicalCondition idiopathic constipation / organ disease / inflammatory bowel disease / headache / GI disorders / dysfunction / nausea / bloating / colitis / respiratory tract infections / chronic / non-cancer pain Effectiveness / fatigue / ADVERSE EFFECTS Constipation Diarrhea Nausea Abdominal Pain Flatulence Abdominal Distension Viral Gastroenteritis Headache Dyspnea / gut hypersensitivity / disorder / cystic fibrosis transmembrane conductance regulator / diarrhea / serious GI disease / sinusitis / constipation / another disease / back pain / spinal cord injury / functional bowel disorder / toxic megacolon / abdominal pain / severe / diarrhea-predominant irritable bowel syndrome / thrombophlebitis / chronic condition / cancer / gastroenteritis / Dyspnea / chronic / Crohn’s disease / migraine / severe constipation / ischemic colitis / ileus / chronic idiopathic constipation / postinfective bowel dysfunction / fever / ulcerative colitis / pain / vomiting / Parkinson’s disease / opioid-induced constipation / chest tightness / dizziness / irritable bowel syndrome / depression / anemia / syndrome / / MedicalTreatment psychological therapies / alternative therapies / / Organization American Gastroenterological Association / Pharmacy and Therapeutics committee / FDA / Medicaid Agency / / Person Review Lubiprostone (Amitiza) / / Position physician / / Product Lotronex / polyethylene glycol / Amitiza / ketoconazole / atropine / lactulose / anti-nociceptive system / INDICATIONS Drug / / ProvinceOrState Ohio / / Technology PHARMACOKINETICS / /
SocialTag |
Irritable Bowel Syndrome Therapeutic Class Review (TCR) March 10, 2014 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording